Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06744465 · ClinicalTrials.gov registry record · NA

NearWave Optical Molecular Monitoring

A NA study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT06744465 is a NA study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 15 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06744465, a NA study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

Interventions

  • DEVICE NearWave monitoring

Study Locations (1)

Indiana

  • Indiana University Simon Comprehensive Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-03-07
Est. Completion 2027-01
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT06744465

The ClinicalTrials.gov registry entry for NCT06744465 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which NearWave monitoring is the first listed.

NCT06744465 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT06744465 about?

NCT06744465 is a clinical study titled "NearWave Optical Molecular Monitoring". The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

What is the current status of trial NCT06744465?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-03-07. Estimated completion is 2027-01.

What conditions does trial NCT06744465 study?

This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer, HER2-Negative Breast Cancer, Invasive Breast Carcinoma, TNBC - Triple-Negative Breast Cancer.

What interventions are being tested in trial NCT06744465?

The interventions under investigation include: NearWave monitoring (DEVICE).

Who is sponsoring clinical trial NCT06744465?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06744465 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.